Court Blasts FDA Over Pravachol Generic Launch

Law360, New York (October 24, 2005, 12:00 AM EDT) -- The FDA abused its discretion by triggering too early Teva Pharmaceutical Inc.’s 180-day market exclusivity for a generic cholesterol drug, according to a federal court’s order granting injunctive relief to the company.

In July, Israel-based Teva sued the U.S. Food and Drug Administration over a decision that effectively wiped out the company’s marketing exclusivity for pravastatin, the generic version of Bristol-Myers Squibb Co.'s Pravachol.

The suit, filed in the U.S. District Court for the District of Columbia, sought to reverse the FDA’s decision and enjoin the...
To view the full article, register now.